Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: Data from the Berlin AFibACS registry

Cardiology Journal

Volumn 21, Issue 5, 2014, Pages 465-473

  Maier, Birga ^a   Hegenbarth, Claire ^a   Theres, Heinz ^b   Schoeller, Ralph ^c   Schuehlen, Helmut ^d   Behrens, Steffen ^e  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c German Red Cross Hospital   (Germany)

^d Vivantes Auguste Viktoria Klinikum   (Germany)

^e Vivantes Klinikum Spandau   (Germany)

Author keywords

Acute myocardial infarction; Antithrombotic therapy; Atrial fibrillation; Registry data; Triple therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DABIGATRAN; HEPARIN; PHENPROCOUMON; PRASUGREL; TICAGRELOR; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BALLOON CATHETER; BARE METAL STENT; BLEEDING; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; COMORBIDITY; DRUG ELUTING STENT; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; SCORING SYSTEM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT; TREATMENT OUTCOME; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; FOLLOW UP; GERMANY; INCIDENCE; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGISTER; RISK ASSESSMENT; RISK FACTOR; STROKE; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BERLIN; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL RATE;

EID: 84908272253     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2013.0146     Document Type: Article

References (31)

1. Camm AJ, Lip GYH, De Caterina R et al. 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation. Eur Heart J, 2012; 33: 2719-2747.
2. Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Vorhofflimmern: Prävalenz und Risikofaktorenprofil in der Allgemeinbevölkerung. Dtsch Arztebl, 2012; 109: 293-299.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007; 146: 857-867.
4. Wilke T, Groth A, Müller S et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Thromb Haemost, 2012; 107: 1053-1065.
5. Lip GYH, Huber K, Andreotti F et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/Stenting. Thromb Haemost, 2010; 103: 13-28.
6. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012; 33: 2569-2619.
7. Hamm CW, Bassand J-P, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J, 2011; 32: 2999-3054.
8. Paikin JS, Wright DS, Crowther MA et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation, 2012: 121: 2067-2070.
9. Eikelboom JW, Menta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute myocardial infarction. Circulation, 2006; 114: 774-782.
10. Lip GYH, Andreotti F, Fauchier L et al. Bleeding risk assessment and management in atrial fibrillation patients. Thromb Haemost, 2011; 106:997-1011.
11. Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. Eur Heart J, 2010; 31: 2369-2429.
12. Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J, 2012; 33: 2719-2747
13. Faxon DP, Eikelboom JW, Berger PB et al. Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thromb Haemost, 2011; 106: 572-584.
14. Huber K, Airaksinen KJ, Cuisset T, Marin F, Rubboli A, Lip GYH. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe. Thromb Haemost, 2011; 106: 569-571.
15. Mega J, Carreras ET. Antithrombotic therapy: triple therapy or triple threat? Hematology, 2012; 1: 547-552.
16. Dewilde WJ, Oirbans T, Verheugt FW et al.; for the WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; 381: 1107-15.
17. Lamberts M, Olesen JB, Ruwald MH et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study. Circulation, 2012; 126: 1185-1193.
18. Yang TH, Jin HY, Choi KN et al. Randomized comparison of new dual antiplatelet therapy (aspirin, prasugrel) and triple antiplatelet therapy (aspirin, clopidogrel, clistazol) using P2Y12 point-of-care-assay in patients with STEMI undergoing primary PCI. Int J Cardiol, 2013; 168: 207-211.
19. Rubboli A, DeWilde W, Huber K et al. The Management of patients on oral anticoagulation undergoing coronary stent implantation. J Intervent Cardiol, 2012; 25: 163-169.
20. Maier B, Thimme W, Schoeller R, Fried A, Behrens S, Theres H. Improved therapy and outcome for patients with acute myocardial infarction: Data of the Berlin Myocardial Infarction Registry from 1999 to 2004. Int J Cardiol, 2008; 130: 211-219.
21. Thygesen K, Alpert JS, White HD; on behalf of the Joint ESC//ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Third universal definition of myocardial infarction. Eur Heart J, 2012; 33: 2551-2568.
22. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: A systematic review of the incidence, clinical features and prognostic implications. Eur Heart J, 2009; 30: 1038-1045.
23. Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace, 2011; 13: 1110-1117.
24. Ahmad Y, Kirchhof P. Gone fishing (for silent atrial fibrillation). Circulation, 2013; 127: 870-872.
25. Lopes RD, Granger CB, Wang TY et al. Atrial fibrillation and acute myocardial infarction: Antithrombotic therapy and outcomes. Am J Med, 2012; 125: 897-905.
26. McManus DD, Huang W, Domakonda KV et al. Trends in atrial fibrillation in patients hospitalized with acute coronary syndrome. Am J Med, 2012; 125: 1076-1084.
27. Smith JG, Wieloch M, Koul S et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention, 2012; 8: 672-678.
28. Connolly SJ, Ezekowitz MD, Yusuf S et al.; the RELY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361: 1139-1151.
29. Patel MR, Mahaffey KW, Garg J et al.; the ROCKET AF Steering Committee for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891.
30. Granger CB, Alexander JH, McMurray JJV et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992.
31. Taylor J. A focused update to the ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J, 2012; 33: 2623-2624.